Market open

INmune Bio/$INMB

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Ticker

$INMB

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boca Raton, United States

Employees

Website

www.inmunebio.com

INmune Bio Metrics

BasicAdvanced

$132M

-

-$2.19

1.85 -

Price and volume

Market cap

$132M

Beta

1.85

52-week high

$14.74

52-week low

$4.32

Average daily volume

297K

Financial strength

Current ratio

2.594

Quick ratio

2.53

Long term debt to equity

0.734

Total debt to equity

7.532

Interest coverage (TTM)

-23.93%

Management effectiveness

Return on assets (TTM)

-44.97%

Return on equity (TTM)

-98.97%

Valuation

Price to revenue (TTM)

2,678.812

Price to book

3.41

Price to tangible book (TTM)

5.96

Price to free cash flow (TTM)

-4.368

Growth

Revenue change (TTM)

-81.25%

Earnings per share change (TTM)

43.07%

3-year revenue growth (CAGR)

13.14%

3-year earnings per share growth (CAGR)

11.22%

What the Analysts think about INmune Bio

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for INmune Bio stock.

INmune Bio Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

INmune Bio Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

INmune Bio News

AllArticlesVideos

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

Seeking Alpha·2 weeks ago

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Seeking Alpha·2 weeks ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INMB

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for INmune Bio stock?

INmune Bio (INMB) has a market cap of $132M as of January 15, 2025.

What is the P/E ratio for INmune Bio stock?

The price to earnings (P/E) ratio for INmune Bio (INMB) stock is 0 as of January 15, 2025.

Does INmune Bio stock pay dividends?

No, INmune Bio (INMB) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next INmune Bio dividend payment date?

INmune Bio (INMB) stock does not pay dividends to its shareholders.

What is the beta indicator for INmune Bio?

INmune Bio (INMB) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.